JNJ fell 5% after EPS dropped 7.5% even as revenue grew 6% to $25.4bn, the $5.5bn talc charge doing the damage. Innovative Medicines is growing enough to offset patent expiries, but MedTech is the dra

What happened: Johnson & Johnson (JNJ) reported Q3 earnings. A talc litigation resolution offer impacted earnings, and MedTech slowed growth. Why it matters: The article attributes the earnings impact to the talc resolution offer and notes slower growth in the MedTech division. Total characters: 259

Talc resolution offer and MedTech slowdown drove Johnson & Johnson Q3 earnings impact.

Talc resolution offer and MedTech slowdown drove Johnson & Johnson Q3 earnings impact. — impact context not separately stored; see What changed.